Association of -Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.

Background And Objectives: Brain amyloid deposition, a major risk factor for Alzheimer disease (AD), is currently estimated by measuring CSF or plasma amyloid peptide levels or by PET imaging. Assessing genetic risks relating to amyloid deposition before any accumulation has occurred would allow for earlier intervention in persons at increased risk for developing AD. Previous work linking amyloid burden and genetic risk relied almost exclusively on , a major AD genetic risk factor.

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Background: Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome proliferator-activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with this condition.

Methods: In this 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 100 patients who had had an inadequate response to ursodeoxycholic acid according to the Paris 2 criteria to receive bezafibrate at a daily dose of 400 mg (50 patients), or placebo (50 patients), in addition to continued treatment with ursodeoxycholic acid.

Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.

Background: Improved understanding is needed of risk factors and markers of disease progression in preclinical Alzheimer's disease. We assessed associations between brain β-amyloidosis and various cognitive and neuroimaging parameters with progression of cognitive decline in individuals with preclinical Alzheimer's disease.

Methods: The INSIGHT-preAD is an ongoing single-centre observational study at the Salpêtrière Hospital, Paris, France.

Fluorescent nanodiamond tracking reveals intraneuronal transport abnormalities induced by brain-disease-related genetic risk factors.

Brain diseases such as autism and Alzheimer's disease (each inflicting >1% of the world population) involve a large network of genes displaying subtle changes in their expression. Abnormalities in intraneuronal transport have been linked to genetic risk factors found in patients, suggesting the relevance of measuring this key biological process. However, current techniques are not sensitive enough to detect minor abnormalities.

[When and why start insulin in type 2 diabetes?].

Insulin initiation is a major step in medical management and life of patients with type 2 diabetes. Insulin is necessary if combination of 2 or 3 oral antidiabetic agents fail to achieve target glycemic goals, especially if HbA1c are superior to 1% from target or weight loss. Insulin will be started with bedtime intermediate-acting insulin.

Functional analysis of the Saccharomyces cerevisiae DUP240 multigene family reveals membrane-associated proteins that are not essential for cell viability.

The DUP240 gene family of Saccharomyces cerevisiae is composed of 10 members. They encode proteins of about 240 amino acids which contain two predicted transmembrane domains. Database searches identified only one homologue in the closely related species Saccharomyces bayanus, indicating that the DUP240 genes encode proteins specific to Saccharomyces sensu stricto.

[A possible alternative in failure of percutaneous intracoronary fibrinolysis: percutaneous endoluminal dilatation].

The authors report three cases of myocardial infarction in which an attempt at intra-coronary fibrinolysis in the acute phase was either transiently effective or totally ineffective. In these three cases, percutaneous endoluminal dilatation was possible allowing restoration of correct coronary flow. The place of percutaneous angioplasty is therefore discussed either immediately after fibrinolysis, when the risk of re-thrombosis appears to be greatest or perhaps in the absence of an attempt at clot lysis, when fibrinolytic treatment is contra-indicated.